Together with Lexeo Therapeutics’ ongoing study of LX2006, a total of 11 participants have been treated to date; includes patients at treatment durations out to 18-months with no treatment-related serious adverse events observed across either study
Interim readout of combined data set at multiple doses expected mid-year 2024
Under the license agreement, Lexeo has acquired certain rights1 including rights to current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy (NCT05302271). The agreement will support Lexeo’s efforts to develop a potentially life-changing therapy for this unmet need.
The investigator-initiated trial is being conducted by Weill Cornell Medicine, which has pioneered groundbreaking research on the potential of gene therapy in FA, published preclinical data that supported the first ever gene therapy IND clearance for FA, and sponsored a natural history study for almost a decade to better characterize the condition and its progression. Lexeo previously licensed know-how relating to AAVrh.10hFXN from Weill Cornell Medicine and collaborated with researchers there to further study the candidate, which Lexeo refers to as LX2006. Lexeo is studying LX2006 in the company-sponsored, open label, dose-ascending, multicenter SUNRISE-FA Phase 1/2 trial (NCT05445323), in which four patients have been dosed to date across cohorts 1 & 2. Weill Cornell Medicine has dosed seven patients to date with LX2006 across dose cohorts 1 & 2 and is collecting biomarker, structural, and functional cardiac data akin to SUNRISE-FA.
“The larger aggregate data set, combined with Orphan Drug, Rare Pediatric Disease, and Fast Track designations from FDA, is anticipated to facilitate an accelerated path to regulatory engagements for LX2006,” said
The interim clinical data readout of LX2006 is expected mid-year 2024. With the newly-licensed data, the readout will now include participants across the two studies, approximately doubling the number of evaluable patients and including patients with a treatment duration out to 18-months. Lexeo also expects to provide an analysis of natural history data and baseline characteristics for study participants from both studies to characterize the cardiovascular disease phenotype seen in FA cardiomyopathy ahead of the interim readout.
“This agreement with
Patients Treated with LX2006 Across Clinical Trials, as of
Dose | Combined Enrollment Update and Months of Follow-Up | ||
>12 months | 6-12 months | <6 months | |
Dose Cohort 1 1.8x1011 vg/kg | 3 | 3 | - |
Dose Cohort 2 5.6x1011 vg/kg | - | 2 | 3 |
Note: Cardiac biopsies are performed only in the SUNRISE-FA trial; one patient in dose cohort 1 and three patients in dose cohort 2 have undergone cardiac biopsies.
The Phase 1A study of AAVrh.10hFXN conducted by investigators at Weill Cornell Medicine is a single-site, 52-week, dose-ascending, open-label trial evaluating the safety and preliminary efficacy of AAVrh.10hFXN in patients who have FA cardiomyopathy. AAVrh.10hFXN is administered as a one-time intravenous infusion to patients in two ascending-dose cohorts with five participants per cohort. While cardiac biopsies are not collected in this study, key cardiac disease measures are collected at 3, 6 and 12-month intervals and complement data collected in SUNRISE-FA.
SUNRISE-FA is a multicenter, 52-week, dose-ascending, open-label trial evaluating the safety and preliminary efficacy of LX2006 in patients who have FA cardiomyopathy. LX2006 is administered as a one-time intravenous infusion to patients in at least two ascending-dose cohorts with the potential to escalate to a third cohort at a dose of 1.2x1012 vg/kg. Long-term safety and efficacy will be evaluated for five years following dosing in both trials.
________________________
1The license agreement includes a package of intellectual property rights including know-how previously licensed to the Company, patent rights related to LX2006, and rights to current and future data generated in an ongoing investigator-initiated Phase 1A trial of AAVrh.10hFXN to treat FA cardiomyopathy (NCT05302271).
About LX2006
LX2006 is an AAV-based gene therapy candidate delivered intravenously for the treatment of FA cardiomyopathy, the most common cause of mortality in patients with FA affecting approximately 5,000 patients in
About Lexeo Therapeutics
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, our expectations and plans regarding our current product candidates and programs, including statements regarding the anticipated benefits of the license agreement between
Media Response:
(619) 849-5382
Carolyn.hawley@inizioevoke.com
Investor Response:
(858) 525-2047
stephen@gilmartinir.com
Source:
2024 GlobeNewswire, Inc., source